Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron

Archive

« Older Entries Newer Entries »

Neuravi Announces Completion of Patient Enrollment in Clinical Trial of a Novel Stent Retriever for Acute Ischemic Stroke Tuesday, February 21st, 2017

ARISE II Data Will Be Submitted to the FDA in Support of Market Clearance for EmboTrap in the U.S. Galway, Ireland — 21 February 2017 — Neuravi, a company dedicated to improving clinical outcomes for st [...]

Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers Tuesday, January 31st, 2017

Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the course of 2016 Reported unaudited FY 2016 revenue and strong year-end cash position Amsterdam, the N [...]

Kuros closes acquisition of Xpand creating a leading commercial-stage orthobiologics company Tuesday, January 31st, 2017

Schlieren (Zurich), Switzerland, January 25, 2017 - Kuros closes acquisition of Xpand creating a leading commercial-stage orthobiologics company Kuros Biosciences (SIX:KURN) today announced the closing of the all-shar [...]

BioCapital Europe 2017, organised by LSP Friday, January 27th, 2017

BioCapital Europe 2017, organised by LSP, is pleased to announce the keynote speaker - Avril Daly, CEO of Retina International and VP of EURORDIS – Rare Disease Europe. Avril Daly is the CEO of Retina Int [...]

LSP's portfolio company Atlas Genetics raises $35m in Series D fundraising Monday, January 23rd, 2017

Financing global launch and menu development of Atlas Genetics’ io® molecular testing system Bath, UK, 23 January, 2017. Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics com [...]

Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies Monday, January 23rd, 2017

UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of its [...]

LSP’s portfolio company G-Therapeutics named FierceMedicalDevices' 2016 Fierce 15 company Monday, January 23rd, 2017

Amsterdam, The Netherlands, January 23, 2017. It is with great pleasure that LSP, the specialist European healthcare investment firm, announces that its portfolio company G-Therapeutics has been named by FierceBiotech [...]

Affimed Announces Pricing of Public Offering of Common Stock Friday, January 20th, 2017

Heidelberg, Germany January 20, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the pricing [...]

LSP's portfolio company Luxendo Announces Series A Extension Bringing Total Capital Raised to €8 Million Thursday, January 12th, 2017

Luxendo intends to use funds to drive the uptake of its Single Plane Illumination Microscopes internationally Heidelberg, Germany, 12 January 2017 - Luxendo, a privately held start-up spun out of the Europe [...]

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis Monday, January 9th, 2017

- Topline data from the study expected in second half of 2018 - Breda, the Netherlands / Ghent, Belgium, January 9, 2017 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focuse [...]

« Older Entries Newer Entries »

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

back to archive overview

Archive

Archive

MONTHLY REPORTS